ES2657442T3 - Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de DJ-1 - Google Patents

Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de DJ-1 Download PDF

Info

Publication number: ES2657442T3
Authority: ES; Spain
Prior art keywords: brain damage; protein; body fluid; stroke; mutant
Prior art date: 2003-09-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES10181193.3T

Other languages

English (en)

Spanish (es)

Inventor

Denis Francois Hochstrasser

Jean-Charles Sanchez

Pierre Lescuyer

Laure Allard

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Proteome Sciences PLC

Original Assignee

Electrophoretics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-20

Filing date

2004-09-20

Publication date

2018-03-05

2004-08-27 Priority claimed from GB0419068A external-priority patent/GB0419068D0/en

2004-09-20 Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd

2018-03-05 Application granted granted Critical

2018-03-05 Publication of ES2657442T3 publication Critical patent/ES2657442T3/es

2024-09-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000006931 brain damage Effects 0.000 title abstract description 11
231100000874 brain damage Toxicity 0.000 title abstract description 11
208000029028 brain injury Diseases 0.000 title abstract description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 9
238000001514 detection method Methods 0.000 title description 2
238000002405 diagnostic procedure Methods 0.000 title 1
102000007659 Protein Deglycase DJ-1 Human genes 0.000 abstract description 9
108010032428 Protein Deglycase DJ-1 Proteins 0.000 abstract description 9
208000032109 Transient ischaemic attack Diseases 0.000 abstract description 5
201000010875 transient cerebral ischemia Diseases 0.000 abstract description 5
238000000034 method Methods 0.000 abstract description 3
208000016988 Hemorrhagic Stroke Diseases 0.000 abstract description 2
208000032382 Ischaemic stroke Diseases 0.000 abstract description 2
208000020658 intracerebral hemorrhage Diseases 0.000 abstract description 2
210000001124 body fluid Anatomy 0.000 abstract 4
239000010839 body fluid Substances 0.000 abstract 4
206010018985 Haemorrhage intracranial Diseases 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
208000008574 Intracranial Hemorrhages Diseases 0.000 abstract 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 abstract 1
201000004810 Vascular dementia Diseases 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
238000004393 prognosis Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 15
102000004196 processed proteins & peptides Human genes 0.000 description 15
210000001175 cerebrospinal fluid Anatomy 0.000 description 13
108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 12
102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 12
208000006011 Stroke Diseases 0.000 description 11
238000003745 diagnosis Methods 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000000539 two dimensional gel electrophoresis Methods 0.000 description 5
239000000499 gel Substances 0.000 description 4
101710159080 Aconitate hydratase A Proteins 0.000 description 3
101710159078 Aconitate hydratase B Proteins 0.000 description 3
102000044126 RNA-Binding Proteins Human genes 0.000 description 3
101710105008 RNA-binding protein Proteins 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
230000004481 post-translational protein modification Effects 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
108010072220 Cyclophilin A Proteins 0.000 description 2
208000004552 Lacunar Stroke Diseases 0.000 description 2
102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 2
102000048176 Prostaglandin-D synthases Human genes 0.000 description 2
108030003866 Prostaglandin-D synthases Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
102000003908 Cathepsin D Human genes 0.000 description 1
108090000258 Cathepsin D Proteins 0.000 description 1
102000009265 Cerebrospinal Fluid Proteins Human genes 0.000 description 1
108010073496 Cerebrospinal Fluid Proteins Proteins 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102100030421 Fatty acid-binding protein 5 Human genes 0.000 description 1
101710083187 Fatty acid-binding protein 5 Proteins 0.000 description 1
102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 1
101710118908 Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
102100037733 Fatty acid-binding protein, brain Human genes 0.000 description 1
101710098548 Fatty acid-binding protein, brain Proteins 0.000 description 1
101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
108010081372 NM23 Nucleoside Diphosphate Kinases Proteins 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
102100023206 Neuromodulin Human genes 0.000 description 1
101710144282 Neuromodulin Proteins 0.000 description 1
102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
101710179452 Ubiquitin fusion degradation protein 1 Proteins 0.000 description 1
102100038833 Ubiquitin recognition factor in ER-associated degradation protein 1 Human genes 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000027455 binding Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000005040 ion trap Methods 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
-1 that is Proteins 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Biochemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Analytical Chemistry (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Oncology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
AIDS & HIV (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

ES10181193.3T 2003-09-20 2004-09-20 Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de DJ-1 Expired - Lifetime ES2657442T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GBGB0322063.9A GB0322063D0 (en)	2003-09-20	2003-09-20	Diagnostic method for brain damage-related disorders
GB0322063		2003-09-20
GBGB0414089.3A GB0414089D0 (en)	2003-09-20	2004-06-23	Diagnostic method for brain damage-related disorders
GB0414089		2004-06-23
GB0419068		2004-08-27
GB0419068A GB0419068D0 (en)	2003-09-20	2004-08-27	Diagnostic method for brain damage-related disorders

Publications (1)

Publication Number	Publication Date
ES2657442T3 true ES2657442T3 (es)	2018-03-05

Family

ID=29266361

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ES10181193.3T Expired - Lifetime ES2657442T3 (es)	2003-09-20	2004-09-20	Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de DJ-1
ES10181407.7T Expired - Lifetime ES2657422T3 (es)	2003-09-20	2004-09-20	Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de NDKA
ES04787496.1T Expired - Lifetime ES2657320T3 (es)	2003-09-20	2004-09-20	Método de diagnóstico para trastornos relacionados con el daño cerebral

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
ES10181407.7T Expired - Lifetime ES2657422T3 (es)	2003-09-20	2004-09-20	Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de NDKA
ES04787496.1T Expired - Lifetime ES2657320T3 (es)	2003-09-20	2004-09-20	Método de diagnóstico para trastornos relacionados con el daño cerebral

Country Status (4)

Country	Link
CA (1)	CA2932077C (fr)
DK (1)	DK1664795T3 (fr)
ES (3)	ES2657442T3 (fr)
GB (2)	GB0322063D0 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009282117B2 (en) *	2008-08-11	2016-05-12	Banyan Biomarkers, Inc.	Biomarker detection process and assay of neurological condition
CN109696549B (zh) *	2017-10-20	2022-11-01	成都蓝瑙生物技术有限公司	用于脑中风的发光elisa体外诊断试剂盒

2003
- 2003-09-20 GB GBGB0322063.9A patent/GB0322063D0/en not_active Ceased
2004
- 2004-06-23 GB GBGB0414089.3A patent/GB0414089D0/en not_active Ceased
- 2004-09-20 CA CA2932077A patent/CA2932077C/fr not_active Expired - Lifetime
- 2004-09-20 ES ES10181193.3T patent/ES2657442T3/es not_active Expired - Lifetime
- 2004-09-20 ES ES10181407.7T patent/ES2657422T3/es not_active Expired - Lifetime
- 2004-09-20 DK DK04787496.1T patent/DK1664795T3/en active
- 2004-09-20 ES ES04787496.1T patent/ES2657320T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2932077C (fr)	2020-06-02
ES2657422T3 (es)	2018-03-05
GB0414089D0 (en)	2004-07-28
GB0322063D0 (en)	2003-10-22
ES2657320T3 (es)	2018-03-02
DK1664795T3 (en)	2018-02-12
CA2932077A1 (fr)	2005-03-31

Publication	Publication Date	Title
JP5019878B2 (ja)	2012-09-05	脳障害関連疾患の診断のためのマーカーの検出に関する方法
Zhang et al.	2007	Aurora B phosphorylates multiple sites on mitotic centromere-associated kinesin to spatially and temporally regulate its function
ES2336946T3 (es)	2010-04-19	Metodo de diagnostico para trastornos relacionados con daño cerebral.
ES2274869T3 (es)	2007-06-01	Diagnostico de tauopatias determinando la relacion tau/fosfotau.
ES2533086T3 (es)	2015-04-07	Método para el diagnóstico de una enfermedad neurodegenerativa
US11726099B2 (en)	2023-08-15	Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
US20210270847A1 (en)	2021-09-02	Protein and peptide biomarkers for traumatic injury to the central nervous system
US20070264197A1 (en)	2007-11-15	Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents
ES2828507T3 (es)	2021-05-26	Un autoanticuerpo novedoso diagnósticamente relevante
JP2005511063A (ja)	2005-04-28	アルツハイマー病を検出する方法およびアルツハイマー病と他の痴呆疾患とを区別する方法、関連のペプチドおよびその使用
US9977036B2 (en)	2018-05-22	Diagnostic markers for multiple sclerosis
WO2012065176A2 (fr)	2012-05-18	Protéines citrullinées:modification post-traduction de protéines myocardiques comme marqueur de maladie physiologique et pathologique
Cohen et al.	1978	Cerebrospinal fluid myelin basic protein and multiple sclerosis
ES2657422T3 (es)	2018-03-05	Método de diagnóstico para trastornos relacionados con el daño cerebral basado en la detección de NDKA
ES2294196T3 (es)	2008-04-01	Metodos para elaborar y utilizar complejos solubles de proteinas diana y chaperonas peptil prolil isomerasas.
WO2012136871A1 (fr)	2012-10-11	Méthode de diagnostic de la maladie d'alzheimer qui utilise le sfrp1 comme biomarqueur
Plubell et al.	2024	B-249 Assessing Targeted Mass Spectrometry Assay Performance for Putative Biomarker Proteins on a New Hybrid Nominal Mass Instrument
KR100582683B1 (ko)	2006-05-23	타겟단백질에 대해 차별적으로 결합되는 단백질 발굴 방법
ES2908917T3 (es)	2022-05-04	Dispositivo de ensayo cardiaco de una etapa
BR102020012760B1 (pt)	2024-11-19	Veículo diagnosticamente útil, kit, método para diagnosticar uma infecção, composição e uso de uma proteína
ES2498465B1 (es)	2015-09-17	Método de diagnóstico y/o pronóstico de la enfermedad de alzheimer
CN112180096A (zh)	2021-01-05	用于诊断线虫感染的新测定法
HRP20080563A2 (hr)	2010-08-31	Proteomski profil i metode detekcije proteina u krvnoj plazmi
Haley	1996	Detection of Alzheimer's disease and other diseases using an improved photoaffinity labeling method
ES2793801A1 (es)	2020-11-16	Metodo para predecir la respuesta terapeutica a farmacos inhibidores de la serina-treonina kinasa braf